Investment analysts at Jefferies Group cut their price objective on shares of Rambus (NASDAQ:RMBS) from $15.00 to $13.50 in a note issued to investors on Friday. Jefferies Group’s price target indicates a potential upside of 10.93% from the company’s current price. Rambus Inc. (NASDAQ:RMBS) belongs to Technology sector. Its net profit margin is -0.90% and weekly performance is 0.52%. On last trading day company shares ended up $12.47. Rambus Inc. (NASDAQ:RMBS) distance from 50-day simple moving average (SMA50) is 0.72%.

Pfizer Inc. (NYSE:PFE) has approached Actavis Plc (ACT) to express its interest in an acquisition, people with knowledge of the matter said, as the U.S. drugmaker continues to explore ways to cut its tax rate and gain a new product pipeline. Pfizer Inc. (NYSE:PFE) shares fell -0.43% in last trading session and ended the day at $30.05. PFE Gross Margin is 81.30% and its return on assets is 17.20%. Pfizer Inc. (NYSE:PFE) quarterly performance is 3.48%.

National Instruments Corp. (NASDAQ:NATI) Director Jeffrey L. Kodosky sold 4,000 shares of National Instruments Corp. stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $32.22, for a total transaction of $128,880.00. Following the completion of the transaction, the director now directly owns 402,826 shares in the company, valued at approximately $12,979,054. On 23 September, National Instruments Corporation (NASDAQ:NATI) shares fell -1.23% and was closed at $31.20. NATI EPS growth in last 5 year was -2.10%. National Instruments Corporation (NASDAQ:NATI) year to date (YTD) performance is -1.05%.

Stifel Nicolaus initiated coverage on shares of ExOne (NASDAQ:XONE) in a research note released on Friday morning, TheFlyOnTheWall.com reports. The firm issued a hold rating on the stock.The ExOne Company (NASDAQ:XONE) ended the last trading day at $25.53. Company weekly volatility is calculated as 4.76% and price to cash ratio as 6.58. The ExOne Company (NASDAQ:XONE) showed a weekly performance of -2.89%.

Gentex (NASDAQ:GNTX)‘s stock had its “neutral” rating reiterated by equities researchers at JPMorgan Chase & Co. in a research report issued on Monday. They currently have a $36.00 price target on the stock, up from their previous price target of $33.00. JPMorgan Chase & Co.’s price objective suggests a potential upside of 26.18% from the stock’s current price. Gentex Corp. (NASDAQ:GNTX) shares fell -1.70% in last trading session and ended the day at $28.05. GNTX Gross Margin is 38.80% and its return on assets is 15.00%. Gentex Corp. (NASDAQ:GNTX) quarterly performance is -2.72%.